Indeed, combination therapies targeting different BCL2-family members, including BCL2, MCL1 apoptosis regulator, and/or BCL2-like 1, have shown synergistic antileukemic effects in T-ALL cells, both in vitro and in vivo [151,152]. Here, BCL2 is linked to acute lymphoblastic leukemia.